Scott L. Burrows - Dec 22, 2023 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role: Chief Financial Officer
Signature: /s/ Heidy King-Jones, by power of attorney
Stock symbol: SYRE
Transactions as of: Dec 22, 2023
Transactions value $: $0
Form type: 4
Date filed: 12/22/2023, 06:00 PM
Previous filing: Sep 5, 2023
Next filing: Feb 2, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SYRE	Common Stock	Award	$0	+135K		$0.00	135K	Dec 22, 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents 134,953 restricted stock units ("RSUs") granted under the Spyre Therapeutics, Inc. 2016 Equity Incentive Plan, as Amended and Restated. Each RSU represents a contingent right to receive, upon vesting, one share of common stock, par value $0.0001 per share, of the Issuer. The RSUs vest as to one-fourth on each anniversary of September 1, 2023, subject to the Reporting Person's continued employment with the Issuer.

Content

Represents 134,953 restricted stock units ("RSUs") granted under the Spyre Therapeutics, Inc. 2016 Equity Incentive Plan, as Amended and Restated. Each RSU represents a contingent right to receive, upon vesting, one share of common stock, par value $0.0001 per share, of the Issuer. The RSUs vest as to one-fourth on each anniversary of September 1, 2023, subject to the Reporting Person's continued employment with the Issuer.